Last reviewed · How we verify
Candida albicans Skin Test Antigen
At a glance
| Generic name | Candida albicans Skin Test Antigen |
|---|---|
| Also known as | Candin® |
| Sponsor | Nielsen BioSciences, Inc. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Candin for the Treatment of Common Warts (PHASE3)
- Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata (NA)
- Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts (PHASE4)
- Candin Safety & Efficacy Study for the Treatment of Warts (PHASE2)
- Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) (PHASE2)
- Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts (PHASE3)
- Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485) (PHASE2)
- Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candida albicans Skin Test Antigen CI brief — competitive landscape report
- Candida albicans Skin Test Antigen updates RSS · CI watch RSS
- Nielsen BioSciences, Inc. portfolio CI